Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;51(10):1638-1648.
doi: 10.1007/s00595-021-02248-y. Epub 2021 Mar 7.

Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer

Jin Moriyama  1 , Yoko Oshima  2 , Tatsuki Nanami  2 , Takashi Suzuki  2 , Satoshi Yajima  2 , Fumiaki Shiratori  2 , Kimihiko Funahashi  2 , Hideaki Shimada  3   4   5
Affiliations

Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer

Jin Moriyama et al. Surg Today. 2021 Oct.

Abstract

Purpose: We evaluated the clinical impact of the carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) values at the time of recurrence in gastric cancer patients.

Methods: Among 790 patients with R0 resected gastric cancer without neoadjuvant therapy between 2004 and 2017, 89 recurrence cases were retrospectively evaluated. The clinical impact of CEA and CA19-9 values on recurrence sites and post-recurrent prognosis were evaluated using univariate and multivariate analyses.

Results: The positive rates of CEA and CA19-9 at recurrence were significantly higher than the preoperative positive rates (CEA, 56% vs 24%; CA19-9, 37% vs 15%). Although CA19-9-positive patients at recurrence exhibited a poor survival, the difference was not significant. The positive rates of CEA at liver or lymph node recurrence were significantly higher than the preoperative positive rates. The positive rate of CA19-9 at peritoneal recurrence was significantly higher than the preoperative positive rate. CA19-9-positive patients at recurrence exhibited worse prognosis than CA19-9-negative patients, although the difference was not significant. At lymph node recurrence, CA19-9-positive patients exhibited a significantly worse survival than CA19-9-negative patients.

Conclusion: In recurrent gastric cancer, the positive status of CA19-9 at recurrence might have a negative prognostic impact after recurrence; particularly, in patients with lymph node recurrence.

Keywords: CA19-9; CEA; Gastric cancer; Prognosis; Recurrence.

PubMed Disclaimer

References

    1. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–64. - DOI
    1. Oshima Y, Suzuki T, Yajima S, Nanami T, Shiratori F, Funahashi K, et al. Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery. Surg Today. 2020;50:1402–8. - DOI
    1. Ito M, Oshima Y, Yajima S, Suzuki T, Nanami T, Shiratori F, et al. Diagnostic impact of high serum midkine level in patients with gastric cancer. Ann Gastroenterol Surg. 2019;3:195–201. - DOI
    1. Hoshino I, Nabeya Y, Takiguchi N, Gunji H, Ishige F, Iwatate Y, et al. Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers. Ann Gastroenterol Surg. 2020;4:275–82. - DOI
    1. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the task force of the Japanese gastric cancer association. Gastric Cancer. 2014;17:26–33. - DOI

LinkOut - more resources